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Abstract: The biodynamics of ultrasmall and small superparamagnetic iron oxide (USPIO and 
SPIO, respectively) particles that were injected intraperitoneally into 36 C57BL/6 mice were 
investigated chronologically. Their distribution was studied histologically at six time points by 
measuring iron-positive areas (µm2) in organ sections stained with Prussian blue. The uptake 
of the differently sized particles was also compared by cultured murine macrophages (J774.1). 
Iron-positive areas in the liver were significantly larger in the mice injected with USPIO than 
those injected with SPIO at the first three time points (P , 0.05). The amount of USPIO 
in the lung parenchyma around the airway was larger than that of SPIO at four time points 
(P , 0.05); distribution to the lymph nodes was not significantly different. The amount of iron 
was significantly larger in SPIO- than USPIO-treated cultured cells (P , 0.05). In conclusion, 
it is suggested that intra peritoneally injected USPIO particles could be used more quickly 
than SPIO to make Kupffer images of the liver and that both agents could help get lymph node 
images of similar quality.
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Introduction
The uptake of superparamagnetic iron oxide (SPIO) particles by cells of the mononu-
clear phagocytic system (MPS) results in hepatic, splenic, bone marrow, and nodal iron 
accumulation.1,2 The selective accumulation of these particles by the MPS is exploited 
at organ-specific magnetic resonance imaging (MRI).3–10 The biodynamics of iron 
oxide nanoparticles vary depending on particle diameter. Unlike SPIO preparations 
comprised of large particles and magnetite microspheres (mean particle diameter, 
72 nm and 1–5 µm, respectively), ultrasmall superparamagnetic iron oxide (USPIO) 
particles (mean diameter, 18 nm) are not immediately recognized by the hepatic and 
splenic MPS.11,12 The resultant prolongation of its intravascular half-life, together 
with its   inherent T1 shortening properties, render USPIO a useful magnetic resonance 
angiography blood-pool agent.13,14 In contrast to large-particle superparamagnetic 
agents, the size of USPIO particles allows the extravasation of USPIO through capillary 
pores, the diameters of which range from 5 to 100 nm, and this capillary permeability 
facilitates the uptake of USPIO in MPS cells throughout the body.15
Although information on the biodynamics of iron oxide nanoparticles of different 
diameters is important for various organ-specific MRI studies, to date this issue has 
not been addressed histologically. Therefore, a comparative histological study of the 
sequential biodynamics of USPIO and SPIO was performed.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Material and methods
Shiga University of Medical Science’s animal experimenta-
tion committee approved all experimental protocols and all 
experiments were conducted in accordance with the animal 
care guidelines of the university.
Iron oxide nanoparticles
Two kinds of iron oxide were studied: USPIO (Meito Sangyo 
Co, Ltd, Kiyosu, Aichi, Japan) and SPIO (Resovist®; I’rom 
Pharmaceutical Co, Ltd, Shinagawa-ku, Tokyo, Japan). The 
mean particle diameters and iron concentrations of USPIO and 
SPIO were 30 nm and 56 mg/mL and 57 nm and 28 mg/mL, 
respectively. Average diameter of the magnetic core was the 
same (5 nm) in both particle types. The iron oxide core of 
both particle types was coated with dextran; their magnetic 
susceptibility was almost the same (about 0.027 cgs).
In vivo study
USPIO or SPIO was injected intraperitoneally (500 µmol Fe/kg) 
into 8-week-old female C57BL/6 mice (Japan SLC, Inc, Tokyo, 
Japan), each weighing approximately 30 g. Groups of three 
mice each were treated with USPIO or SPIO and sacrificed at 
time points of 30 minutes and 1, 3, 12, 24, and 48 hours after-
ward; two mice were the controls. Organs to be studied were 
fixed in 10% paraformaldehyde and examined histologically.
histological examination
The mice were sacrificed at the indicated time points and their 
organs were removed for histological study. Sections of the 
right lobe of the liver were cut in the axial plane; splenic sec-
tions were also cut in the axial plane and included the hilum. 
Lung sections were cut in the coronal plane and included 
the hilum. Sections from the heart, great vessels, gastro-
intestinal tract, and kidney were cut in the coronal plane. 
Sections (4 µm in thickness) of paraffin-embedded organs 
were stained with Prussian blue to identify the accumulation 
of iron oxide. Macrophages were immuno  histochemically 
stained with F4/80. Areas stained with Prussian blue 
and F4/80 were compared. For quantitative assessment, 
Prussian-blue-stained areas (µm2) in a single field of view 
(magnification ×200) of three different lesions for each 
histological section were measured using Image-Pro® Plus 
software (Media Cybernetics, Bethesda, MD) and average 
values were calculated.
In vitro study
To compare phagocytosis of USPIO and SPIO by cultured 
cells murine macrophage cell line J774.1 (RIKEN Cell Bank, 
Wako, Saitama, Japan) was used, which is widely used in 
research on macrophages.16–18 Cells (5 × 104) were seeded 
in 12-well multiple well culture plates (Costar®; Corn-
ing Inc, Corning, NY) and grown at 37°C for 24 hours in 
1 mL of growth medium (RPMI-1640; Nacalai Tesque, Inc, 
Kyoto, Japan) supplemented with 10% (v/v) fetal bovine 
serum (FBS) (Invitrogen Ltd, Carlsbad, CA) and 1% (w/v) 
penicillin and streptomycin solution (Nacalai Tesque, Inc). 
After 24 hours, the medium was replaced, USPIO or SPIO 
was added (10 μg : 100 μL) and the plates were incubated 
for 1 hour for cell labeling. After this, the medium was 
again replaced and the wells then incubated for 24 hours. To 
identify intracellular iron oxide accumulation, the cells were 
stained with Prussian blue. The amount of iron contained 
in cell lysates by atomic absorption photometry (AA-6800; 
Shimadzu Co, Kyoto, Japan) was measured. Cell labeling 
was as described in a previous study.19
statistical analysis
Statistical analysis was carried out using Dr SPSS II for 
Windows (SPSS Japan Inc, Tokyo, Japan). Differences in 
the uptake of USPIO and SPIO in murine tissues and the 
uptake of iron by cultured cells were determined with the 
one-tailed Student’s t-test. A P-value , 0.05 was considered 
statistically significant.
Results
Quantitative histological analysis
Quantitative analysis based on the measurement of Prussian-
blue-stained areas revealed that iron-positive areas in the 
liver were larger in the mice injected with USPIO than 
those injected with SPIO at almost all time points except 
the last one (828 vs 0 µm2 at 30 minutes, 1299 vs 297 µm2 
at 1 hour, 3647 vs 853 µm2 at 3 hours, 2256 vs 1497 µm2 
at 12 hours, 1885 vs 1168 µm2 at 24 hours, and 1948 vs 
2483 µm2 at 48 hours), as shown in Figures 1 and 2. The 
difference was significant at 30 minutes, 1, and 3 hours 
(P , 0.05). USPIO was quickly distributed throughout the 
liver; its distribution increased until 3 hours postinjection 
and decreased thereafter. On the other hand, the distribution 
of SPIO occurred more slowly and increased over a longer 
period of time. Unlike USPIO, SPIO was not detected in 
the liver at 30 minutes. Iron-positive areas at the hepatic 
sinusoid corresponding to the area harboring Kupffer cells 
coincided with macrophage-positive F4/80-stained areas, 
as shown in Figure 3.
In lung specimens, a few USPIO and SPIO particles were 
observed early; they were located in the parenchyma around International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 1 Histological study of mouse liver specimens stained with Prussian blue (magnification ×200). (A), (B), (C): 30 minutes, 1, and 3 hours, respectively, after 
intraperitoneal (IP) injection of ultrasmall superparamagnetic iron oxide. (D), (E), (F): 30 minutes, 1, and 3 hours, respectively, after IP injection of small superparamagnetic 
iron oxide.
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Figure 2 comparison of Prussian-blue-stained areas (µm2) in the liver. At 30 minutes, 1, and 3 hours after intraperitoneal injection, iron-positive areas were significantly 
larger in mice treated with ultrasmall superparamagnetic iron oxide (UsPIO) than with small superparamagnetic iron oxide (sPIO).
Note: *P , 0.05.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1590
Tsuchiya et al
ABC
DEF
Figure 4 Prussian-blue staining of lung parenchyma around the airway (magnification ×200). (A), (B), (C): 30 minutes, 3, and 48 hours, respectively, after intraperitoneal (IP) 
injection of ultrasmall superparamagnetic iron oxide. (D), (E), (F): 30 minutes, 3, and 48 hours, respectively, after IP injection of small superparamagnetic iron oxide.
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Figure  3  Histological  study  of  the  liver  of  mice  sacrificed  48  hours  after  the 
intraperitoneal  administration  of  ultrasmall  superparamagnetic  iron  oxide.   
(A) Prussian-blue and (B) F4/80 stain (magnification ×200). Iron-positive areas were 
located at the hepatic sinusoid corresponding to the area harboring Kupffer cells and 
were consistent with areas positive for immunohistochemical staining.
the airway and their number was increased dramatically at 
3 hours postinjection and decreased thereafter, as shown in 
Figure 4. At all time points, iron positive areas in the lung 
parenchyma were larger in the mice injected with USPIO 
than those injected with SPIO (65 vs 29 at 30 minutes, 
149 vs 52 at 1 hour, 4812 vs 1364 at 3 hours, 906 vs 201 at 
12 hours, 616 vs 167 at 24 hours, and 288 vs 249 at 48 hours), 
as shown in Figure 5. In addition, at 30 minutes, 1, 3, and 
24 hours the iron-positive areas were significantly larger in 
mice injected with USPIO (P , 0.05).
Both USPIO and SPIO were abundant at all time points 
in mediastinal lymph nodes; there was no difference between 
the two groups of mice (P . 0.05), as shown in Figures 6 and 7. 
As in liver specimens, iron-positive areas coincided with 
macrophages in lung and lymph node samples.
There was no significant accumulation in the heart, great 
vessels, kidneys, or gastrointestinal tract. As the controls 
harbored abundant stores of iron, visualized as Prussian-
blue-positive areas, macroscopically it was observed that 
there was almost no difference between them and USPIO- 
or SPIO-treated mice with respect to the spleen. Control 
mice manifested no significant iron deposits in organs other 
than the spleen.
In vitro study
While almost all cultured J774.1 cells phagocytized USPIO 
and SPIO, the amount of intracellular iron measured by 
atomic absorption photometry was significantly higher in 
cells treated with SPIO than with USPIO (695 vs 108 pg/cell, 
P , 0.05), as shown in Figure 8.
Discussion
To our knowledge, this is the first study comparing the biody-
namics of intraperitoneally injected USPIO and SPIO. SPIO 
(Resovist) is the contrast agent used in MRI and generally 
its safety in the clinical setting has already been established. 
USPIO used in this study is different in particle size from that 
of SPIO, but very similar in composition. Ferumoxtran-10, 
similar to the USPIO used in this study, was well tolerated 
in phase I and II studies in adult humans.20,21 In addition, in 
a safety study conducted in adult rabbits, no inflammation 
or fibrosis occurred after intraperitoneal (IP) injection of International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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Figure 5 comparison of Prussian-blue-stained areas (µm2) in the lung parenchyma. The iron-positive areas were significantly larger in mice intraperitoneally injected with 
ultrasmall superparamagnetic iron oxide (UsPIO) than with small superparamagnetic iron oxide (sPIO) at 30 minutes, 1, 3, and 24 hours.
Note: *P , 0.05.
NC100150, a USPIO similar to ferumoxtran-10.22 IP iron-
dextran supplementation is known to be effective and safe 
in correcting iron deficiency in rats and humans.23,24 In our 
study, IP injection was safe and never caused the death of 
any mouse.
USPIO was distributed to the liver as early as 30 minutes 
postinjection; it peaked at 3 hours and decreased thereafter. 
SPIO appeared later and its distribution throughout the liver 
increased over time. At 12 hours postinjection, the hepatic 
distribution of both agents was comparable. A greater 
amount of USPIO than SPIO tended to be distributed to 
the lung parenchyma around the airway, possibly because 
USPIO was presented more easily to the small lymphatic 
vessels around the airway. There was no significant differ-
ence in lymph node accumulation between the two groups 
of mice.
The early distribution of intraperitoneally injected 
USPIO to the liver and the absence of significant differ-
ences in the lymph node distribution of USPIO and SPIO 
are primarily attributable to differences in the absorption 
route. The trapping of intravenously administered USPIO 
by reticuloendothelial cells in the liver and spleen has International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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Figure  6  Prussian-blue  staining  of  mediastinal  lymph  nodes  (magnification  ×100).  (A),  (B):  30  minutes  and  1  hour  after  intraperitoneal  (IP)  injection  of  ultrasmall 
superparamagnetic iron oxide. (C), (D): 30 minutes and 1 hour after IP injection of small superparamagnetic iron oxide.
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Figure 7 comparison of distribution of ultrasmall superparamagnetic iron oxide (UsPIO) and small superparamagnetic iron oxide (sPIO) in the lymph nodes.
Note: P . 0.05 at all time points.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 8 comparison of the amount of intracellular iron measured by atomic 
absorption photometry. The amount of intracellular iron was significantly higher in 
cells treated with small superparamagnetic iron oxide (sPIO) than with ultrasmall 
superparamagnetic iron oxide (UsPIO).
Note: *P , 0.05.
been reported to be difficult because the particle diameter 
is small and the particles persist in the blood.11,12 Lukas 
et al25 who studied the absorption route of intraperitoneally 
administered compounds, suggested that particles absorbed 
by the subperitoneal capillary system reached the liver via 
the hepatic portal system. The earlier hepatic distribution 
of USPIO suggests that it is delivered via this pathway. 
Intercellular spaces directly open to lymphatic vessels are 
present in the mesothelial layer of the peritoneum. The peri-
toneal cavity is the origin of two major lymphatic networks: 
the thoracic duct drains the retroperitoneal region and enters 
the left subclavian vein; the right lymphatic duct collects 
lymph from parasternal and intercostal-paravertebral 
lymph ducts and drains mainly through the diaphragm and, 
ultimately, into the right subclavian vein. In the former net-
work, lymph passes through iliac, renal, splenic, posterior 
gastric, portal, superior mesenteric, and cisternal lymph 
nodes; in the latter network it passes through more distal 
(eg, parathymic) and left and right posterior mediastinal 
lymph nodes.26,27 The authors posited that there was not 
only USPIO present in abundant amounts in the lymphatic 
tracts due to these networks but also SPIO, which tended to 
be trapped in the liver with only slight distribution to the 
lymph nodes.
Cultured macrophages absorbed SPIO more readily than 
USPIO. Under conditions where the same number of macro-
phages respond to iron oxide compounds containing the same 
amount of iron, larger particles are recognized more easily. 
This is consistent with the hypothesis that upon intravenous 
(IV) infusion, reticuloendothelial cells in the liver and spleen 
trap SPIO more readily than USPIO.
This study had some limitations. First, the number of mice 
was too small for an accurate elucidation of the pharmaco-
kinetics and prevented the exclusion of interindividual dif-
ferences. Second, it could not be confirmed that the minute 
amounts of USPIO and SPIO used were injected accurately 
into the   peritoneal cavity. In some instances, the agent might 
have been injected subcutaneously or into the bowel. Third, 
due to technical challenges, the pharmacokinetics of intrave-
nously delivered USPIO or SPIO was not studied. However, 
considering the mechanisms by which USPIO reached the 
liver earlier than SPIO and the result that similar amounts 
of USPIO and SPIO were distributed throughout the lymph 
nodes, it is important to compare the differences of distribu-
tion between USPIO and SPIO via two different injection 
routes (IP and IV).
The findings suggest that the IP delivery of both USPIO 
and SPIO might be useful as a contrast agent for the study of 
lymph nodes in a clinical setting. The IP delivery of USPIO 
might also be used as a contrast agent for studying the liver. 
As IP delivery is not a popular injection route in clinical set-
tings, drugs or contrast agents are currently intraperitoneally 
injected in limited cases of patients with cancer, peritonitis, 
or chronic renal failure requiring continuous ambulatory 
peritoneal dialysis (CAPD).24,28–30 Although clinical applica-
tion is limited, the authors suggest, for cases of patients with 
ascites of unknown origin, that intraperitoneally injected iron 
particles may be very useful for getting Kupffer images of the 
liver and lymph node images to help diagnose metastases in 
these areas. Also, in cases of iron-deficient CAPD patients, 
intraperitoneally injected iron dextran has potential for fill-
ing both roles, as a route of entry in iron therapy and as a 
contrast agent for the liver and lymph nodes. In addition, 
depending on the diameter of the administered particles, it 
may be possible to deliver agents other than USPIO and SPIO 
intraperitoneally for the study of various organs.
Conclusion
This study suggests that intraperitoneally injected USPIO 
could be used more quickly than SPIO can to make Kupffer 
images of the liver and that both agents could help get lymph 
node images of similar quality.
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